摘要
目的探讨钙剂在腹膜透析患者中的应用指征及药学监护。方法选取26例进行腹膜透析的患者作为研究对象,分析钙剂的应用指征,实施药学监护。结果治疗前,患者的血清钙浓度为(1.96±0.22)mmol/L,钙磷乘积为(2.94±0.71)mmol^2/L^2,甲状旁腺素(iPTH)为(24.81±9.12)pg/ml;治疗3个月后分别为(2.17±0.16)mmol/L、(2.77±0.68)mmol^2/L^2、(21.13±7.56)pg/ml;治疗3个月后血清钙浓度高于治疗前,差异有统计学意义(P<0.05);而钙磷乘积和甲状旁腺素指标与治疗前比较差异无统计学意义(P>0.05)。结论在腹膜透析患者应用钙剂时,要根据患者机体血磷水平和甲状旁腺素指标调整,严密监测,保证钙剂的合理使用,促进患者用药安全。
Objective To explore the application indications and pharmaceutical care of calciumpreparations in patients with peritoneal dialysis.Methods A total of26patients with peritoneal dialysis as studysubjects,and analysis was made on application indications of calcium preparations to perform pharmaceuticalcare.Results Before treatment,patients had serum calcium concentrations as(1.96±0.22)mmol/L,calciumphosphorusproduct as(2.94±0.71)mmol2/L2,parathyroid hormone(iPTH)as(24.81±9.12)pg/ml,which wererespectively(2.17±0.16)mmol/L,(2.77±0.68)mmol2/L2and(21.13±7.56)pg/ml after3months of treatment.Patients had higher serum calcium concentrations after3months of treatment than that before treatment,and thedifference had statistical significance(P<0.05).Patients had no statistically significant difference in calciumphosphorusproduct and parathyroid hormone comparing those before treatment(P>0.05).Conclusion Calciumpreparations should be adjusted according to the body's blood phosphorus levels and intact parathyroid hormoneindex when it applied in peritoneal dialysis patients,and strict monitoring should be given to ensure the rationaluse of calcium preparations and promote patients’medication safety.
作者
肖勇辉
XIAO Yong-hui(Guangdong Province Meizhou City Hospital of Traditional Chinese Medicine, Meizhou 514021, China)
出处
《中国现代药物应用》
2017年第9期98-99,共2页
Chinese Journal of Modern Drug Application
关键词
钙剂
腹膜透析
应用指征
药学监护
Calcium preparations
Peritoneal dialysis
Application indications
Pharmaceutical care
